Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

This study tests whether adding lutetium-PSMA (a targeted radiation treatment delivered through the blood) to stereotactic radiotherapy (precise, high-dose radiation) works better than radiation alone for prostate cancer patients with a small number of metastases (spread to 1–3 spots). **You may be eligible if...** - You have prostate cancer with 1–3 metastatic lesions each no larger than 5 cm - Your PSMA PET scan shows those same spots - Your primary prostate tumor has already been treated with surgery and/or radiation - You have had salvage radiation to the prostate bed or pelvis **You may NOT be eligible if...** - You have more than 3 metastatic lesions - Your PSMA PET scan does not match the spots found on other scans - Your primary tumor has not been treated Talk to your doctor to see if this trial is right for you.